Pilette C
Cliniques universitaires St-Luc et Institut de Recherche expérimentale & clinique, Service et Pôle de Pneumologie, Université catholique de Louvain, Bruxelles.
Bull Mem Acad R Med Belg. 2011;166(7-9):280-7; discussion 288-9.
Asthma is one of the most common chronic diseases, affecting 5-10% of the population worldwide. It is closely associated with the "atopic" hypersensitivity to environmental antigens ('allergens'), which is mediated by specific IgE driven by a T helper 2-type immune response, also promoting recruitment of eosinophils and mast cells and mucus overproduction. Our first research axis showed that allergen immunotherapy in patients with allergic rhinitis and asthma to grass pollen induces inhibition of the IL-9/ mast cells axis and a selective induction of allergen-specific IgA2 antibodies in serum, which correlated to nasal tissue expression of TGF-beta. We further showed that these IgA antibodies, whilst unable to inhibit IgE-facilitated allergen presentation by B cells as achieved by IgG4 antibodies, could trigger IL-10 expression in monocytes and dendritic cells through activation of p38 MAP-kinase and recruitment of sp1 and NFkappaB transcription factors. In addition, results in a murine model of asthma suggested a protective role of secretory IgA. A second research axis, exploring local immune responses to lung allergen exposure, identified the CCR4 pathway as critically mediating the recruitment of Th2 cells into the lung of atopic asthmatics. In patients with non-atopic (intrinsic) asthma, we recently reported on the local production of specific IgE to mite allergens (Der p), able to activate basophils in vitro, while lung challenge to Der p in vivo did not result into asthmatic responses. Altogether, we showed (1) that allergen immunotherapy triggers production of IgA2, which could be protective through induction of IL-10 in monocytes/dendritic cells and/ or by scavenging allergens within secretions, and (2) that allergen exposure, which triggers the recruitment of Th2 cells through the CCR4 pathway, induces locally the production of specific IgE, irrespectively of systemic atopic features, supporting the concept according which "second signals" condition in vivo the inception and exacerbations of asthma.
哮喘是最常见的慢性疾病之一,影响着全球5%至10%的人口。它与对环境抗原(“过敏原”)的“特应性”超敏反应密切相关,这种超敏反应由辅助性T2型免疫反应驱动的特异性IgE介导,还会促进嗜酸性粒细胞和肥大细胞的募集以及黏液过度产生。我们的第一个研究方向表明,对草花粉过敏的鼻炎和哮喘患者进行过敏原免疫疗法可抑制IL-9/肥大细胞轴,并在血清中选择性诱导过敏原特异性IgA2抗体,这与鼻组织中转化生长因子-β的表达相关。我们进一步表明,这些IgA抗体虽然不能像IgG4抗体那样抑制B细胞介导的IgE促进的过敏原呈递,但可以通过激活p38丝裂原活化蛋白激酶以及募集sp1和核因子κB转录因子来触发单核细胞和树突状细胞中IL-10的表达。此外,哮喘小鼠模型的结果表明分泌型IgA具有保护作用。第二个研究方向是探索对肺部过敏原暴露的局部免疫反应,发现CCR4途径在介导特应性哮喘患者Th2细胞向肺部募集中起关键作用。在非特应性(内因性)哮喘患者中,我们最近报道了针对螨过敏原(Der p)的特异性IgE在局部产生,这种IgE能够在体外激活嗜碱性粒细胞,而体内对Der p进行肺部激发并未引发哮喘反应。总之,我们表明:(1)过敏原免疫疗法可触发IgA2的产生,其可通过在单核细胞/树突状细胞中诱导IL-10和/或通过清除分泌物中的过敏原起到保护作用;(2)过敏原暴露通过CCR4途径触发Th2细胞募集,无论全身特应性特征如何,都会在局部诱导特异性IgE的产生,这支持了“第二信号”决定哮喘在体内起始和加重的概念。